TOLEDO, Ohio -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that it has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable the pharmaceutical and life science industries to advance discoveries and deliver groundbreaking treatments to patients.

Financial Post

Canada

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research

Media Bias/Fact Check

Leon Cooperman

Allianz

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

Medical Device News Magazine

NAMSA Acquires The U.S. Medical Device Testing Operations Of WuXi AppTec, Solidifying Its Position As The Leader In MedTech Testing And Clinical Research - Medical Device News Magazine

NAMSA Solidifies Position as the Leader in MedTech Testing and Clinical Research TOLEDO, OHIO USA –—NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that is has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable the pharmaceutical and life science indus…

Medical Alley Association

NAMSA Acquires the US Medical Device Testing Operations of WuXi AppTec - Medical Alley

Plus, news about Neurizon:
WuXi AppTec divests again: The company is selling its US medical device testing operations, including facilities in Minnesota and Georgia to medtech consulting firm NAMSA, according to ...

Endpoints News

WuXi AppTec sells medical device testing unit; Layoffs at Notch Therapeutics

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

pharmaceutical-technology.com

JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast - Pharmaceutical Technology

NAMSA acquires WuXi AppTec's US-based medical device testing operations to strengthen its medtech clinical research testing capabilities.The post NAMSA acquires WuXi AppTec’s US medical device testing facilities appeared first on Medical Device Network.

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics